Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...
DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...
DexCom, a leading manufacturer of continuous glucose monitoring systems, is confronting one of the most significant challenges in its corporate history. Regu ...
Zacks.com on MSN
Insulet Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
PODD's Q3 earnings and revenues top forecasts, with strong Omnipod growth and margin expansion lifting shares.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its financial results for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback